ABSTRACT
A llergic rhinitis (AR) affects up to 60 million individuals in the
United States. 1 Depending on the allergen sensitivity profile of an individual, AR can be classified as perennial AR (PAR), seasonal AR (SAR), or mixed (typically PAR with seasonal flares). 2 AR exerts a substantial impact on patients' quality of life and productivity and on health care costs. 3, 4 The total direct annual medical costs of AR are $3.4 billion, with one-half attributed to prescription drugs. 4 Intranasal corticosteroids (INCSs) are the first line of treatment recommended for AR. 5, 6 In the United States, because of the implementation of The Montreal Protocol (1987) on Substances that Deplete the Ozone Layer in 2003, only aqueous nasal sprays of INCSs have been available. 7, 8 Hydrofluoroalkane (HFA) propellants provide an acceptable alternative to chlorofluorocarbons and have been used safely in metereddose inhalers (MDIs) for pulmonary delivery for Ͼ10 years. 7 Ciclesonide (CIC), a corticosteroid prodrug, is enzymically converted by esterases to its active metabolite, desisobutyryl CIC, which displays a substantially higher affinity (120-fold) for the glucocorticoid receptor compared with the parent compound. 9, 10 An aqueous nasal spray of CIC is available for the treatment of nasal symptoms in patients Ն6 years of age with SAR and patients Ն12 years of age with PAR. 11 CIC nasal aerosol using a nasal MDI with an HFA propellant (CIC-HFA) is now available for the treatment of symptoms associated with PAR and SAR in individuals aged Ն12 years. 12 Certain sensory attributes of INCSs, such as rundown to the back of the throat, run-out from the nose, and nasal irritation, can influence patient treatment preferences and, perhaps, patient adherence to therapy. [13] [14] [15] [16] Findings from the Allergies in America adult survey and The Nasal Allergy Survey Assessing Limitations reveal that ϳ40% of patients with AR report rundown to the back of the throat as a bothersome side effect of their intranasal aqueous medications and as a common reason for patients requesting a change in their AR medication. 1, 17 This study, for the first time, compared the nasal deposition and retention of CIC-HFA aerosol with mometasone furoate monohydrate aqueous nasal spray (MFNS) in subjects with AR, using a radioactive tracer as a surrogate for deposition and retention of the vehicle for each of these nasal formulations.
MATERIALS AND METHODS

Subjects
Subjects aged 18-65 years with confirmed, symptomatic PAR or SAR (subjects were required to have a minimum cumulative subjectassessed instantaneous total nasal symptom score of 8 from a possible 12) were included in the study. Subjects showed sensitivity to at least one allergen known to induce PAR (house-dust mite, animal dander, cockroach, or molds) or SAR (grass, tree, or weed pollen), established by a skin-prick test with a wheal diameter of Ն3 mm. Subjects who had radiation exposure, including from the present study, Ͼ5 mSv within the last 12 months or 10 mSv within the last 5 years were excluded. Subjects occupationally exposed to radiation as defined in the Ionizing Radiations Regulations 1999 18 also were not permitted to participate. Subjects who had an abnormality on physical examina- 
Study Design and Administration of Radiolabeled Formulations
In this open-label, single-dose, single-site crossover study, subjects were randomized to receive a single dose of radiolabeled 74-g CIC-HFA (1 actuation/each nostril, 37 g/actuation containing Յ5 MBq of technetium-99m [ 99m Tc] in 2 actuations, 1/nostril) via a nasal aerosol MDI (Fig. 1 A) or a single dose of radiolabeled 200-g MFNS (2 actuations/each nostril, 50 g/actuation containing Յ5 MBq of 99m Tc in 4 actuations, 2/nostril) via an aqueous nasal pump spray (Fig. 1 B; ClinicalTrials.gov identifier NCT01371786). Subjects refrained from taking other medications for AR during the study.
This study was approved by the Medicines and Healthcare Products Regulatory Agency and an Institutional Review Board. Written informed consent was provided by all subjects. This study was conducted in accordance with the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects and performed by Quotient Clinical (United Kingdom). Administration of radioactive substances was approved by the Department of Health (United Kingdom) Administration of Radioactive Substances Advisory Committee.
Assessments
The primary assessment was to quantify, as a percentage of the delivered dose of radioactivity, the amount of the radiolabeled vehicle of CIC-HFA and the amount of the radiolabeled vehicle of MFNS deposited in the nasal cavity over a 10-minute time period postdose. Secondary assessments included the amount of radiolabeled CIC-HFA and radiolabeled MFNS retained in the nasal cavity over 10 minutes, the initial amount deposited in the nasopharynx and on nasal wipes initially and over 10 minutes, and the differences in nasal deposition between groups initially at ϳ2 minutes and over 10 minutes postdose.
Radiolabeling Methodology
Radiolabeling methods using 99m Tc were established before the study to allow in vivo deposition and retention to be measured. Performance verification studies were conducted to confirm that both radiolabeled drug formulations behaved similarly to nonlabeled drug formulations. Specifically, in vitro experiments were performed to develop and validate the radiolabeling method with respect to the key delivery characteristics of the treatments under investigation.
99m Tc was mixed into commercially available formulations of MFNS and CIC-HFA, where the radiolabeled formulation denoted deposition and retention of the vehicle for the respective formulations.
Scintigraphic Assessments
Scintigraphic images were taken immediately (ϳ2 minutes) after each dose (Fig. 2, A and B ) and continued at ϳ2-minute intervals until 10 minutes postdose. A gamma camera (MAXICAMERA; General Electric Co., Schenectady, NY) with a 40-cm field of view and fitted 
Figure 2. Representative scintigraphic images, at the 2-minute postdose time point, for (A) ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) and (B) mometasone furoate monohydrate aqueous nasal spray (MFNS).
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with a low-energy parallel-hole collimator was used. Images were acquired with subjects either sitting or standing in front of the gamma camera. Scintigraphic image data were viewed and analyzed through the Micas X camera operating system (Bartec; Camberley, Surrey, UK).
The following parameters were determined: (1) initial deposition of radioactivity (percentage of delivered dose of radioactivity) in the nasal cavity, in the nasopharynx, and on nasal wipes, with subjects having been instructed to use at least 1 wipe at each 2-minute assessment point and (2) retention of radioactivity (percentage of delivered dose of radioactivity) in the nasal cavity and on nasal wipes at 2-minute intervals during the first 10 minutes postdose. The amount of radioactivity cleared into the nasopharynx was calculated by subtracting the amount of radioactivity quantified in the nasal cavity and that quantified on nasal wipes from the delivered dose. Data were corrected for background radiation and radioactive decay. Correction for attenuation of gamma rays due to overlying tissue was performed using a transmission scan according to standard methods. 19 
Statistical Analyses
The population included for the scintigraphic data analysis consisted of all subjects in the intent-to-treat population who received administration of a radiolabeled solution/suspension, had scintigraphic images of sufficient number and quality available, and had completed the transmission scan. Summary statistics were gathered for all scintigraphic parameters. The time points included in the analysis were 2, 4, 6, 8, and 10 minutes postdose. Between-group differences were assessed by a mixed model repeated measures analysis with factors for treatment, sequence, period, and time point. A first-order autoregressive variance-covariance structure was used for the random error, and subjects nested within sequence were used to specify the covariance matrix for repeated measures. For both treatment groups, the least squares mean and standard error of the least squares mean were determined. For all analyses, p Յ 0.05 was considered significant. The p values for differences in retention within the nasal cavity, nasopharynx, and wipes between the radiolabeled nasal CIC-HFA and radiolabeled MFNS were unadjusted for multiplicity.
RESULTS
Subject Demographics and Disposition
A total of 14 subjects (10 male and 4 female subjects) were enrolled in the study (Table 1 ). All subjects received at least 1 dose of study medication and were included in the intent-to-treat and scintigraphy data analysis populations. However, for the statistical analysis of scintigraphic data, 13 subjects were included, because 1 subject was excluded because that patient reported that the first actuation of radiolabeled MFNS failed to deliver the required dose.
Scintigraphy Assessments
Both CIC-HFA solution and MFNS suspension were successfully labeled with 99m Tc, with the required level of radioactivity (2.0-5.0 MBq) delivered per dose. All five scintigraphic images (images recorded at 2-minute intervals) were completed within 2-10 minutes postdose.
The initial deposition (2 minutes postdose) of radioactivity within the nasal cavity was significantly higher in the radiolabeled CIC-HFA group (shown in a representative scintigraphic image at 2 minutes postdose in Fig. 2 A) compared with the radiolabeled MFNS group (shown in a representative scintigraphic image at 2 minutes postdose in Fig. 2 B; 99.42% versus 86.50%; p ϭ 0.0046; Table 2 , Fig. 3 ). In addition, for each of the five scintigraphic evaluations over 10 minutes, the retention of radioactivity for the radiolabeled CIC-HFA group was significantly higher than for the radiolabeled MFNS group (ranging from 99.42% at 2 minutes to 81.10% at 10 minutes for CIC-HFA versus ranging from 86.50% at 2 minutes to 54.31% at 10 minutes for the MFNS group).
The deposition of radioactivity on nasal wipes was significantly lower at all time points in the radiolabeled CIC-HFA group compared with the radiolabeled MFNS group (Table 2) . No evidence of a time point effect or a treatment-by-time point interaction was observed, suggesting that the magnitude of the treatment effect was consistent across all time points.
Posterior losses of radioactivity to the nasopharynx were similar for the radiolabeled CIC-HFA and the radiolabeled MFNS groups at 2 and 4 minutes postdose but were significantly higher for the MFNS group at 6, 8, and 10 minutes postdose ( Table 2 ). At 10 minutes postdose, mean posterior losses of radioactivity in the radiolabeled CIC-HFA and radiolabeled MFNS groups were 17.19 and 32.13% (p ϭ 0.0003), respectively. Evidence of a time point effect was observed, with a gradual increase in posterior losses in both treatment groups over time.
Safety Assessments
There were no deaths, and no other serious adverse events or events leading to study discontinuation were reported during the study. A total of six events were reported by six subjects (Table 3) ; three events were reported by three subjects after administration of each regimen. The only event considered potentially related to study medication was mild headache reported by one patient after administration of radiolabeled CIC-HFA. There were no events assessed as being severe. The majority of events were mild in severity.
DISCUSSION
This study for the first time reports a comparison of the nasal deposition and retention of a nasal aerosol with that of an aqueous nasal spray. This study used gamma scintigraphy as a surrogate to quantify the nasal deposition of CIC-HFA aerosol compared with that of the aqueous MFNS. This scintigraphic study conducted in subjects with active AR and with therapeutic doses of INCSs showed that the majority of radiolabeled CIC-HFA (99.42%) administered was initially (2 minutes postdose) deposited in the nasal cavity, with negligible runoff into the nasopharynx.
The nasal delivery systems used in this study differed in several key aspects. The delivery device for CIC-HFA aerosol (Fig. 1 A) is comprised of a nasal applicator as well as a canister containing an HFA-propelled solution of CIC, with each actuation delivering a metered spray volume (50 L/spray); the nasal applicator (CIC-HFA aerosol) contains a dose indicator as well, along with a tethered dust cap. The delivery device for MFNS (Fig. 1 B) is comprised of an aqueous pump spray, delivering a 100-L volume of aqueous MFNS suspension with each spray.
For nasal delivery systems, the site of deposition is affected by several parameters, including the volume of delivered dose and velocity of the delivered particles. 20 Drug deposition primarily in 
the nonciliated anterior nasal cavity can slow the clearance, mainly because of a lack of mucociliary clearance and drug absorption. 21 In this study, 19% of the delivered dose of the radiolabeled CIC-HFA formulation was cleared from the nasal cavity at 10 minutes postdose. For radiolabeled MFNS, most (ϳ86%) of the delivered dose also was initially deposited in the nasal cavity; however, the amount of radioactivity retained in the nasal cavity declined by 32% over 10 minutes after dosing, with radioactivity quantified on the nasal wipes and in the nasopharynx increasing over 10 minutes. These differences are consistent with previously published studies using inert particles in healthy adults and suggest that nasal clearance tends to be slower with the use of aerosol MDI delivery systems than with the use of nasal sprays. [21] [22] [23] Deposition of radioactivity on nasal wipes was significantly lower for radiolabeled CIC-HFA compared with that for radiolabeled MFNS at all five time points, suggesting a lower potential for nasal drip. Greater posterior loss to the nasopharynx and run-out from the nose were seen with radiolabeled aqueous MFNS nasal spray over the 10-minute evaluation period.
Data from the Allergies in America adult survey and The Nasal Allergy Survey Assessing Limitations indicate that some patients experience tolerability issues related to nasal irritation, nasal runoff, and rundown to the back of the throat. 17 Clinical studies in subjects with AR suggest that certain sensory attributes of INCSs, including nasal irritation, nasal run-out, and rundown to the back of the throat, can influence patient preference for a particular product. 13, 14 This study was conducted in subjects with AR, unlike most deposition studies, which have been conducted in healthy volunteers. The CIC-HFA nasal aerosol formulation administers a lower spray volume in clinical use relative to most aqueous sprays. The findings in this study may be influenced by the 400-L volume of MFNS (2 sprays/nostril, 100 L/spray) compared with 100 L (1 actuation/ 
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nostril, 50 L/spray) for nasal aerosol CIC-HFA. This difference may have accounted for the higher runoff from the nasal cavity seen with MFNS compared with CIC-HFA. Another source of potential bias in this study was the open-label design of the study, because both the participants and the researchers were aware of which medication was being measured for radioactive deposition. Further bias could have been introduced by the use of two distinctly different devices for medication delivery. In addition, in this study the formulation (vehicle containing the active corticosteroid) was radiolabeled but not the corticosteroid molecule. In vitro assessments showed an acceptable correlation between radioactivity and drug deposition, indicating that the radiolabel acted as a good marker for the deposition of the active moiety. However, the specific distribution of the corticosteroid molecule over the 10-minute evaluation period was not quantified. Finally, this study did not include any efficacy assessments to evaluate the potential clinical implications of differences in deposition between these two formulations because only a single dose was administered.
CONCLUSION
In this scintigraphy study, radiolabeled CIC-HFA delivered via a nasal MDI resulted in significantly higher deposition (Fig. 2 A) and retention in the nasal cavity compared with radiolabeled MFNS (Fig.  2 B) . The CIC-HFA nasal aerosol offers an alternative treatment for patients with AR who may find nasal runoff and rundown to the back of the throat to be bothersome.
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